Financial reports
20-F
2023 FY
Annual report (foreign)
21 Mar 24
20-F
2022 FY
Annual report (foreign)
16 Mar 23
20-F
2021 FY
Annual report (foreign)
17 Mar 22
20-F
2020 FY
Annual report (foreign)
25 Feb 21
20-F
2019 FY
Annual report (foreign)
25 Feb 20
20-F
2018 FY
Annual report (foreign)
25 Mar 19
20-F
2017 FY
Annual report (foreign)
19 Mar 18
20-F
2016 FY
Annual report (foreign)
21 Feb 17
20-F
2015 FY
Annual report (foreign)
25 Jan 16
20-F
2014 FY
Annual report (foreign)
12 Feb 15
Current reports
6-K
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company
21 Mar 24
6-K
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
12 Feb 24
6-K
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
9 Jan 24
6-K
Current report (foreign)
8 Jan 24
6-K
MediWound Secures Additional U.S. Department of Defense Funding to
28 Dec 23
6-K
Current report (foreign)
15 Dec 23
6-K
MediWound Reports Third Quarter 2023 Financial Results and Provides
21 Nov 23
6-K
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer
21 Nov 23
6-K
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
13 Nov 23
6-K
MediWound Secures Additional U.S. Department of Defense Funding to
26 Sep 23
Registration and prospectus
S-8
Registration of securities for employees
15 Aug 23
424B3
Prospectus supplement
6 Apr 23
POS AM
Prospectus update (post-effective amendment)
31 Mar 23
POS EX
Additional exhibits for listing
16 Mar 23
424B3
Prospectus supplement
16 Mar 23
424B3
Prospectus supplement
16 Mar 23
424B5
Prospectus supplement for primary offering
3 Feb 23
424B3
Prospectus supplement
9 Jan 23
424B3
Prospectus supplement
6 Jan 23
424B3
Prospectus supplement
25 Nov 22
Proxies
No filings
Other
EFFECT
Notice of effectiveness
6 Apr 23
EFFECT
Notice of effectiveness
28 Nov 22
CORRESP
Correspondence with SEC
22 Nov 22
UPLOAD
Letter from SEC
16 Nov 22
EFFECT
Notice of effectiveness
6 Jun 22
CORRESP
Correspondence with SEC
1 Jun 22
UPLOAD
Letter from SEC
31 May 22
EFFECT
Notice of effectiveness
23 Apr 19
CORRESP
Correspondence with SEC
18 Apr 19
CORRESP
Correspondence with SEC
12 Apr 19
Ownership
SC 13G/A
Rosalind Advisors, Inc.
14 Feb 24
SC 13G/A
Deep Insight Limited Partnership
8 Jan 24
SC 13G/A
Israel Biotech Fund II, L.P.
8 Jan 24
SC 13D/A
Access Industries Holdings LLC
1 Sep 23
SC 13G/A
ROSENBERG LIOR
14 Feb 23
SC 13D/A
Access Industries Holdings LLC
13 Feb 23
SC 13G
Point72 Asset Management, L.P.
8 Feb 23
SC 13G
Rosalind Advisors, Inc.
21 Dec 22
SC 13G
Deep Insight Limited Partnership
5 Dec 22
SC 13G
Israel Biotech Fund II, L.P.
5 Dec 22